JAK2 and myeloproliferative neoplasm: Murine MPN models with JAK2 V617F and MPL W515L drivers have demonstrated persistent activation of the MAPK mediated by platelet-derived growth factor receptor alpha (PDGFRα) in vivo in the setting of ruxolitinib exposure.